The study is aimed at patients with hormone receptor-positive, HER2-negative breast cancer whose advanced or metastatic disease has not previously been treated with antihormonal therapy +/- CDK4/6 inhibitors. Prior antihormonal therapy in the adjuvant setting is permitted.
The study is aimed at patients with hormone receptor-positive, HER2-negative breast cancer whose advanced or metastatic disease has not previously been treated with antihormonal therapy +/- CDK4/6 inhibitors. Prior antihormonal therapy in the adjuvant setting is permitted.
